ID

30259

Description

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00527735

Lien

https://clinicaltrials.gov/show/NCT00527735

Mots-clés

Versions (1)
  1. 25/05/2018 25/05/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

25 mai 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Lung Cancer NCT00527735

Anglais

Eligibility Lung Cancer NCT00527735

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed lung cancer (stage iiib/iv nonsmall-cell lung cancer or extensive stage small-cell lung cancer [sclc])
Description

Carcinoma of lung | Non-Small Cell Lung Carcinoma TNM clinical staging | Small cell lung cancer extensive stage

Type de données

boolean

Alias
UMLS CUI [1]
C0684249
UMLS CUI [2,1]
C0007131
UMLS CUI [2,2]
C3258246
UMLS CUI [3]
C0278726
measurable tumor lesion (as long as it is not located in a previously irradiated area) as defined by modified world health organization criteria
Description

Measurable Disease | Exception Irradiation Area Previous

Type de données

boolean

Alias
UMLS CUI [1]
C1513041
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1522449
UMLS CUI [2,3]
C0005902
UMLS CUI [2,4]
C0205156
eastern cooperative oncology group performance status of ≤1 at study entry
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
accessible for treatment and follow-up
Description

Accessibility Therapeutic procedure | Accessibility Follow-up

Type de données

boolean

Alias
UMLS CUI [1,1]
C0814423
UMLS CUI [1,2]
C0087111
UMLS CUI [2,1]
C0814423
UMLS CUI [2,2]
C3274571
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
brain metastases
Description

Metastatic malignant neoplasm to brain

Type de données

boolean

Alias
UMLS CUI [1]
C0220650
malignant pleural effusion
Description

Pleural Effusion, Malignant

Type de données

boolean

Alias
UMLS CUI [1]
C0080032
autoimmune disease
Description

Autoimmune Disease

Type de données

boolean

Alias
UMLS CUI [1]
C0004364
motor neuropathy of autoimmune origin
Description

Motor neuropathy Origin Autoimmune process

Type de données

boolean

Alias
UMLS CUI [1,1]
C0235025
UMLS CUI [1,2]
C0439659
UMLS CUI [1,3]
C0443146
sclc-related paraneoplastic syndromes
Description

Paraneoplastic Syndromes Relationship Small cell carcinoma of lung

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030472
UMLS CUI [1,2]
C0439849
UMLS CUI [1,3]
C0149925
any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the cervix or breast; or prostate cancer treated with systemic therapy (participants with a previous malignancy but without evidence of disease for 5 years were allowed to enter the study)
Description

Cancer Other | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix | Exception Carcinoma in situ of female breast | Exception Systemic therapy Prostate carcinoma

Type de données

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0699893
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0851140
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0686288
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C1515119
UMLS CUI [5,3]
C0600139
prior systemic therapy for lung cancer. prior radiation therapy or locoregional surgeries performed later than at least 3 weeks prior to randomization date were allowed.
Description

Systemic therapy Carcinoma of lung | Prior radiation therapy allowed | Operative Surgical Procedures Locoregional Previous allowed

Type de données

boolean

Alias
UMLS CUI [1,1]
C1515119
UMLS CUI [1,2]
C0684249
UMLS CUI [2,1]
C0279134
UMLS CUI [2,2]
C0683607
UMLS CUI [3,1]
C0543467
UMLS CUI [3,2]
C1947913
UMLS CUI [3,3]
C0205156
UMLS CUI [3,4]
C0683607
grade 2 peripheral neuropathy (motor or sensory)
Description

Peripheral motor neuropathy CTCAE Grades | Sensory neuropathy CTCAE Grades

Type de données

boolean

Alias
UMLS CUI [1,1]
C0235025
UMLS CUI [1,2]
C1516728
UMLS CUI [2,1]
C0151313
UMLS CUI [2,2]
C1516728
known hiv or hepatitis b or c infection
Description

HIV Infection | Hepatitis B | Hepatitis C

Type de données

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019163
UMLS CUI [3]
C0019196
chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or noncancer-related illnesses). however, use of corticosteroids was allowed if used as premedication for paclitaxel infusion or for treating immune-related adverse events or adrenal insufficiencies.
Description

Immunosuppressive Agents chronic | CORTICOSTEROIDS FOR SYSTEMIC USE | Exception Paclitaxel Infusion | Exception Adverse event Relationship Immune system | Exception Adrenal Insufficiency Adverse Event

Type de données

boolean

Alias
UMLS CUI [1,1]
C0021081
UMLS CUI [1,2]
C0205191
UMLS CUI [2]
C3653708
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0144576
UMLS CUI [3,3]
C0574032
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0877248
UMLS CUI [4,3]
C0439849
UMLS CUI [4,4]
C0020962
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C1963059
inadequate hematologic function defined by an absolute neutrophil count <1,500/mm^3, a platelet count <100,000/mm^3, or hemoglobin level <9 g/dl.
Description

Hematologic function Inadequate | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C0221130
UMLS CUI [1,2]
C0205412
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0518015
inadequate hepatic function defined by a total bilirubin level >2.0 times the upper limit of normal (uln), or ≥2.5 times the uln if liver metastases are present, aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the uln or
Description

Liver function Inadequate | Elevated total bilirubin | Relationship Secondary malignant neoplasm of liver | Aspartate aminotransferase increased | Alanine aminotransferase increased

Type de données

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C0205412
UMLS CUI [2]
C0741494
UMLS CUI [3,1]
C0439849
UMLS CUI [3,2]
C0494165
UMLS CUI [4]
C0151904
UMLS CUI [5]
C0151905
≥5 times the uln if liver metastases are present.
Description

Aspartate aminotransferase increased | Alanine aminotransferase increased | Relationship Secondary malignant neoplasm of liver

Type de données

boolean

Alias
UMLS CUI [1]
C0151904
UMLS CUI [2]
C0151905
UMLS CUI [3,1]
C0439849
UMLS CUI [3,2]
C0494165
inadequate renal function defined by a serum creatinine level ≥2.5 times the uln
Description

Renal function Inadequate | Serum creatinine raised

Type de données

boolean

Alias
UMLS CUI [1,1]
C0232804
UMLS CUI [1,2]
C0205412
UMLS CUI [2]
C0700225
inadequate creatinine clearance defined as less than 50 ml/min.
Description

Creatinine clearance Inadequate

Type de données

boolean

Alias
UMLS CUI [1,1]
C0812399
UMLS CUI [1,2]
C0205412
Retour au début de la page

Similar models

Eligibility Lung Cancer NCT00527735

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Carcinoma of lung | Non-Small Cell Lung Carcinoma TNM clinical staging | Small cell lung cancer extensive stage
Item
histologically or cytologically confirmed lung cancer (stage iiib/iv nonsmall-cell lung cancer or extensive stage small-cell lung cancer [sclc])
boolean
C0684249 (UMLS CUI [1])
C0007131 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
C0278726 (UMLS CUI [3])
Measurable Disease | Exception Irradiation Area Previous
Item
measurable tumor lesion (as long as it is not located in a previously irradiated area) as defined by modified world health organization criteria
boolean
C1513041 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0005902 (UMLS CUI [2,3])
C0205156 (UMLS CUI [2,4])
ECOG performance status
Item
eastern cooperative oncology group performance status of ≤1 at study entry
boolean
C1520224 (UMLS CUI [1])
Accessibility Therapeutic procedure | Accessibility Follow-up
Item
accessible for treatment and follow-up
boolean
C0814423 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0814423 (UMLS CUI [2,1])
C3274571 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Metastatic malignant neoplasm to brain
Item
brain metastases
boolean
C0220650 (UMLS CUI [1])
Pleural Effusion, Malignant
Item
malignant pleural effusion
boolean
C0080032 (UMLS CUI [1])
Autoimmune Disease
Item
autoimmune disease
boolean
C0004364 (UMLS CUI [1])
Motor neuropathy Origin Autoimmune process
Item
motor neuropathy of autoimmune origin
boolean
C0235025 (UMLS CUI [1,1])
C0439659 (UMLS CUI [1,2])
C0443146 (UMLS CUI [1,3])
Paraneoplastic Syndromes Relationship Small cell carcinoma of lung
Item
sclc-related paraneoplastic syndromes
boolean
C0030472 (UMLS CUI [1,1])
C0439849 (UMLS CUI [1,2])
C0149925 (UMLS CUI [1,3])
Cancer Other | Exception Skin carcinoma | Exception Carcinoma in situ of uterine cervix | Exception Carcinoma in situ of female breast | Exception Systemic therapy Prostate carcinoma
Item
any concurrent malignancy other than nonmelanoma skin cancer; carcinoma in situ of the cervix or breast; or prostate cancer treated with systemic therapy (participants with a previous malignancy but without evidence of disease for 5 years were allowed to enter the study)
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0699893 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0851140 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0686288 (UMLS CUI [4,2])
C1705847 (UMLS CUI [5,1])
C1515119 (UMLS CUI [5,2])
C0600139 (UMLS CUI [5,3])
Systemic therapy Carcinoma of lung | Prior radiation therapy allowed | Operative Surgical Procedures Locoregional Previous allowed
Item
prior systemic therapy for lung cancer. prior radiation therapy or locoregional surgeries performed later than at least 3 weeks prior to randomization date were allowed.
boolean
C1515119 (UMLS CUI [1,1])
C0684249 (UMLS CUI [1,2])
C0279134 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C0543467 (UMLS CUI [3,1])
C1947913 (UMLS CUI [3,2])
C0205156 (UMLS CUI [3,3])
C0683607 (UMLS CUI [3,4])
Peripheral motor neuropathy CTCAE Grades | Sensory neuropathy CTCAE Grades
Item
grade 2 peripheral neuropathy (motor or sensory)
boolean
C0235025 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C0151313 (UMLS CUI [2,1])
C1516728 (UMLS CUI [2,2])
HIV Infection | Hepatitis B | Hepatitis C
Item
known hiv or hepatitis b or c infection
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Immunosuppressive Agents chronic | CORTICOSTEROIDS FOR SYSTEMIC USE | Exception Paclitaxel Infusion | Exception Adverse event Relationship Immune system | Exception Adrenal Insufficiency Adverse Event
Item
chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or noncancer-related illnesses). however, use of corticosteroids was allowed if used as premedication for paclitaxel infusion or for treating immune-related adverse events or adrenal insufficiencies.
boolean
C0021081 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C3653708 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0144576 (UMLS CUI [3,2])
C0574032 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0877248 (UMLS CUI [4,2])
C0439849 (UMLS CUI [4,3])
C0020962 (UMLS CUI [4,4])
C1705847 (UMLS CUI [5,1])
C1963059 (UMLS CUI [5,2])
Hematologic function Inadequate | Absolute neutrophil count | Platelet Count measurement | Hemoglobin measurement
Item
inadequate hematologic function defined by an absolute neutrophil count <1,500/mm^3, a platelet count <100,000/mm^3, or hemoglobin level <9 g/dl.
boolean
C0221130 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0518015 (UMLS CUI [4])
Liver function Inadequate | Elevated total bilirubin | Relationship Secondary malignant neoplasm of liver | Aspartate aminotransferase increased | Alanine aminotransferase increased
Item
inadequate hepatic function defined by a total bilirubin level >2.0 times the upper limit of normal (uln), or ≥2.5 times the uln if liver metastases are present, aspartate aminotransferase and alanine aminotransferase levels ≥2.5 times the uln or
boolean
C0232741 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
C0741494 (UMLS CUI [2])
C0439849 (UMLS CUI [3,1])
C0494165 (UMLS CUI [3,2])
C0151904 (UMLS CUI [4])
C0151905 (UMLS CUI [5])
Aspartate aminotransferase increased | Alanine aminotransferase increased | Relationship Secondary malignant neoplasm of liver
Item
≥5 times the uln if liver metastases are present.
boolean
C0151904 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
C0439849 (UMLS CUI [3,1])
C0494165 (UMLS CUI [3,2])
Renal function Inadequate | Serum creatinine raised
Item
inadequate renal function defined by a serum creatinine level ≥2.5 times the uln
boolean
C0232804 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
C0700225 (UMLS CUI [2])
Creatinine clearance Inadequate
Item
inadequate creatinine clearance defined as less than 50 ml/min.
boolean
C0812399 (UMLS CUI [1,1])
C0205412 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial